1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 73, 2022
  5. Article

Annual Review of Medicine

Volume 73, 2022

Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells

Abstract

We proposed and demonstrated that myelogenous leukemia has a preleukemic phase. In the premalignant phase, normal hematopoietic stem cells (HSCs) gradually accumulate mutations leading to HSC clonal expansion, resulting in the emergence of leukemic stem cells (LSCs). Here, we show that preleukemic HSCs are the basis of clonal hematopoiesis, as well as late-onset blood diseases (chronic-phase chronic myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic disease). The clones at some point each trigger surface expression of “eat me” signals for macrophages, and in the clones and their LSC progeny, this is countered by upregulation of “don't eat me” signals for macrophages such as CD47,opening the possibility of CD47-based therapies. We include evidence that similar processes result in fibroblast expansion in a variety of fibrotic diseases, and arterial smooth muscle clonal expansion is a basis of atherosclerosis, including upregulation of both “eat me” and “don't eat me” molecules on the pathogenic cells.

Keyword(s): atherosclerosis, clonal expansion, leukemia, myelodysplastic syndrome, premalignant progression, stem cells
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042420-104436
2022-01-27
2024-05-14
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-042420-104436.html?itemId=/content/journals/10.1146/annurev-med-042420-104436&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105–11
     [Google Scholar]
  2. 2. 
    Miyamoto T, Weissman IL, Akashi K. 2000. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. PNAS 97:7521–26
     [Google Scholar]
  3. 3. 
    Spangrude GJ, Heimfeld S, Weissman IL 1988. Purification and characterization of mouse hematopoietic stem cells. Science 241:58–62
     [Google Scholar]
  4. 4. 
    Jan M, Snyder TM, Corces-Zimmerman MR et al. 2012. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4:149ra18
     [Google Scholar]
  5. 5. 
    Weissman IL. 2015. Stem cells are units of natural selection for tissue formation, for germline development, and in cancer development. PNAS 112:8922–28
     [Google Scholar]
  6. 6. 
    Lagasse E, Weissman IL 1994. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J. Exp. Med. 179:1047–52
     [Google Scholar]
  7. 7. 
    Wright DE, Wagers AJ, Gulati AP et al. 2001. Physiological migration of hematopoietic stem and progenitor cells. Science 294:1933–36
     [Google Scholar]
  8. 8. 
    Jaiswal S, Jamieson CH, Pang WW et al. 2009. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271–85
     [Google Scholar]
  9. 9. 
    Majeti R, Chao MP, Alizadeh AA et al. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286–99
     [Google Scholar]
  10. 10. 
    Oldenborg PA, Zheleznyak A, Fang YF et al. 2000. Role of CD47 as a marker of self on red blood cells. Science 288:2051–54
     [Google Scholar]
  11. 11. 
    Feng M, Marjon KD, Zhu F et al. 2018. Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nat. Commun. 9:3194
     [Google Scholar]
  12. 12. 
    Beerman I, Bhattacharya D, Zandi S et al. 2010. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. PNAS 107:5465–70
     [Google Scholar]
  13. 13. 
    Pang WW, Price EA, Sahoo D et al. 2011. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. PNAS 108:20012–17
     [Google Scholar]
  14. 14. 
    Dameshek W. 1951. Some speculations on the myeloproliferative syndromes. Blood 6:372–75
     [Google Scholar]
  15. 15. 
    Nowell PC, Hungerford DA. 1960. A minute chromosome in human granulocytic leukemia. Science 132:1497
     [Google Scholar]
  16. 16. 
    Fialkow PJ, Gartler SM, Yoshida A. 1967. Clonal origin of chronic myelocytic leukemia in man. PNAS 58:1468–71
     [Google Scholar]
  17. 17. 
    Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–93
     [Google Scholar]
  18. 18. 
    Ben-Neriah Y, Daley GQ, Mes-Masson AM et al. 1986. The chronic myelogenous leukemia–specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212–14
     [Google Scholar]
  19. 19. 
    Daley GQ, Van Etten RA, Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–30
     [Google Scholar]
  20. 20. 
    Jamieson CHM, Ailles LE, Dylla SJ et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351:657–67
     [Google Scholar]
  21. 21. 
    Abrahamsson AE, Geron I, Gotlib J et al. 2009. Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation. PNAS 106:3925–29
     [Google Scholar]
  22. 22. 
    Levine RL, Wadleigh M, Cools J et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–97
     [Google Scholar]
  23. 23. 
    James C, Ugo V, Le Couedic JP et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–48
     [Google Scholar]
  24. 24. 
    Kralovics R, Passamonti F, Buser AS et al. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779–90
     [Google Scholar]
  25. 25. 
    Baxter EJ, Scott LM, Campbell PJ et al. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–61
     [Google Scholar]
  26. 26. 
    Jamieson CHM, Gotlib J, Durocher JA et al. 2006. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. PNAS 103:6224–29
     [Google Scholar]
  27. 27. 
    Geron I, Abrahamsson AE, Barroga CF et al. 2008. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13:321–30
     [Google Scholar]
  28. 28. 
    Wernig G, Kharas MG, Okabe R et al. 2008. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311–20
     [Google Scholar]
  29. 29. 
    Nangalia J, Massie CE, Baxter EJ et al. 2013. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369:2391–405
     [Google Scholar]
  30. 30. 
    Klampfl T, Gisslinger H, Harutyunyan AS et al. 2013. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369:2379–90
     [Google Scholar]
  31. 31. 
    Mesa R, Jamieson C, Bhatia R et al. 2016. Myeloproliferative neoplasms, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 14:1572–611
     [Google Scholar]
  32. 32. 
    Verstovsek S, Gotlib J, Mesa RA et al. 2017. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J. Hematol. Oncol. 10:156
     [Google Scholar]
  33. 33. 
    Jamieson C, Hasserjian R, Gotlib J et al. 2015. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J. Transl. Med. 13:294
     [Google Scholar]
  34. 34. 
    Grinfeld J, Nangalia J, Baxter EJ et al. 2018. Classification and personalized prognosis in myeloproliferative neoplasms. N. Engl. J. Med. 379:1416–30
     [Google Scholar]
  35. 35. 
    Jiang Q, Isquith J, Ladel L et al. 2021. Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell Rep 34:108670
     [Google Scholar]
  36. 36. 
    Van Egeren D, Escabi J, Nguyen M et al. 2021. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell 28:514–23
     [Google Scholar]
  37. 37. 
    Zipeto MA, Court AC, Sadarangani A et al. 2016. ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis. Cell Stem Cell 19:177–91
     [Google Scholar]
  38. 38. 
    Jiang Q, Isquith J, Zipeto MA et al. 2019. Hyper-editing of cell-cycle regulatory and tumor suppressor RNA promotes malignant progenitor propagation. Cancer Cell 35:81–94
     [Google Scholar]
  39. 39. 
    Papaemmanuil E, Gerstung M, Bullinger L et al. 2016. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374:2209–21
     [Google Scholar]
  40. 40. 
    Cancer Genome Atlas Res. Netw., Ley TJ, Miller C et al. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368:2059–74
     [Google Scholar]
  41. 41. 
    Weissman I. 2005. Stem cell research: paths to cancer therapies and regenerative medicine. JAMA 294:1359–66
     [Google Scholar]
  42. 42. 
    Jan M, Chao MP, Cha AC et al. 2011. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. PNAS 108:5009–14
     [Google Scholar]
  43. 43. 
    Corces-Zimmerman MR, Hong WJ, Weissman IL et al. 2014. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. PNAS 111:2548–53
     [Google Scholar]
  44. 44. 
    Shlush LI, Zandi S, Mitchell A et al. 2014. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506:328–33
     [Google Scholar]
  45. 45. 
    Quek L, David MD, Kennedy A et al. 2018. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat. Med. 24:1167–77
     [Google Scholar]
  46. 46. 
    Corces-Zimmerman MR, Majeti R. 2014. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia 28:2276–82
     [Google Scholar]
  47. 47. 
    Corces MR, Buenrostro JD, Wu B et al. 2016. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48:1193–203
     [Google Scholar]
  48. 48. 
    Desai P, Mencia-Trinchant N, Savenkov O et al. 2018. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24:1015–23
     [Google Scholar]
  49. 49. 
    Abelson S, Collord G, Ng SWK et al. 2018. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559:400–4
     [Google Scholar]
  50. 50. 
    Haferlach T, Nagata Y, Grossmann V et al. 2014. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–47
     [Google Scholar]
  51. 51. 
    Papaemmanuil E, Gerstung M, Malcovati L et al. 2013. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616–27
     [Google Scholar]
  52. 52. 
    Will B, Zhou L, Vogler TO et al. 2012. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 120:2076–86
     [Google Scholar]
  53. 53. 
    Pang WW, Pluvinage JV, Price EA et al. 2013. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. PNAS 110:3011–16
     [Google Scholar]
  54. 54. 
    Woll PS, Kjällquist U, Chowdhury O et al. 2014. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25:794–808 Erratum Cancer Cell 25:861 Erratum Cancer Cell 27:603–5
     [Google Scholar]
  55. 55. 
    Duncavage EJ, Jacoby MA, Chang GS et al. 2018. Mutation clearance after transplantation for myelodysplastic syndrome. N. Engl. J. Med. 379:1028–41
     [Google Scholar]
  56. 56. 
    Feng D, Gip P, McKenna KM, et al 2018. Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia. Blood 132:Suppl. 12729
     [Google Scholar]
  57. 57. 
    Sallman DA, Al Malki M, Asch AS, et al 2020. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results. J. Clin. Oncol. 38:Suppl. 157507
     [Google Scholar]
  58. 58. 
    Pang WW, Czechowicz A, Logan AC et al. 2019. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood 133:2069–78
     [Google Scholar]
  59. 59. 
    Kwon HS, Logan AC, Chhabra A et al. 2019. Anti-human CD117 antibody–mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood 133:2104–8
     [Google Scholar]
  60. 60. 
    Busque L, Mio R, Mattioli J et al. 1996. Nonrandom X-inactivation patterns in normal females: Lyonization ratios vary with age. Blood 88:59–65
     [Google Scholar]
  61. 61. 
    Champion KM, Gilbert JG, Asimakopoulos FA et al. 1997. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br. J. Haematol. 97:920–26
     [Google Scholar]
  62. 62. 
    Genovese G, Kahler AK, Handsaker RE et al. 2014. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371:2477–87
     [Google Scholar]
  63. 63. 
    Jaiswal S, Fontanillas P, Flannick J et al. 2014. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371:2488–98
     [Google Scholar]
  64. 64. 
    Xie M, Lu C, Wang J et al. 2014. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20:1472–78
     [Google Scholar]
  65. 65. 
    Jaiswal S, Natarajan P, Silver AJ et al. 2017. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377:111–21
     [Google Scholar]
  66. 66. 
    Fuster JJ, MacLauchlan S, Zuriaga MA et al. 2017. Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice. Science 355:842–47
     [Google Scholar]
  67. 67. 
    Sano S, Oshima K, Wang Y et al. 2018. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ. Res. 123:335–41
     [Google Scholar]
  68. 68. 
    Sano S, Oshima K, Wang Y et al. 2018. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-β/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71:875–86
     [Google Scholar]
  69. 69. 
    Dorsheimer L, Assmus B, Rasper T et al. 2019. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 4:25–33
     [Google Scholar]
  70. 70. 
    Fuster JJ, Zuriaga MA, Zorita V et al. 2020. TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep 33:108326
     [Google Scholar]
  71. 71. 
    Zink F, Stacey SN, Norddahl GL et al. 2017. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130:742–52
     [Google Scholar]
  72. 72. 
    Buscarlet M, Provost S, Zada YF et al. 2017. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130:753–62
     [Google Scholar]
  73. 73. 
    WHO (World Health Organ.) 2020. The top ten causes of death Fact Sheet WHO Geneva: http://www.who.int/mediacentre/factsheets/fs310/en/
  74. 74. 
    Kennedy LJ Jr., Weissman IL. 1971. Dual origin of intimal cells in cardiac-allograft arteriosclerosis. N. Engl. J. Med. 285:884–87
     [Google Scholar]
  75. 75. 
    Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868–74
     [Google Scholar]
  76. 76. 
    Goldstein JL, Brown MS. 1977. Atherosclerosis: the low-density lipoprotein receptor hypothesis. Metabolism 26:1257–75
     [Google Scholar]
  77. 77. 
    Howson JMM, Zhao W, Barnes DR et al. 2017. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nat. Genet. 49:1113–19
     [Google Scholar]
  78. 78. 
    DiRenzo D, Owens GK, Leeper NJ. 2017.. “ Attack of the clones”: commonalities between cancer and atherosclerosis. Circ. Res. 120:624–26
     [Google Scholar]
  79. 79. 
    Chappell J, Harman JL, Narasimhan VM et al. 2016. Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contribute to neointimal formation in mouse injury and atherosclerosis models. Circ. Res. 119:1313–23
     [Google Scholar]
  80. 80. 
    Benditt EP, Benditt JM. 1973. Evidence for a monoclonal origin of human atherosclerotic plaques. PNAS 70:1753–56
     [Google Scholar]
  81. 81. 
    Kojima Y, Volkmer JP, McKenna K et al. 2016. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536:86–90
     [Google Scholar]
  82. 82. 
    Wang Y, Nanda V, Direnzo D et al. 2020. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade. PNAS 117:15818–26
     [Google Scholar]
  83. 83. 
    Jarr KU, Nakamoto R, Doan BH et al. 2021. Effect of CD47 blockade on vascular inflammation. N. Engl. J. Med. 384:382–83
     [Google Scholar]
  84. 84. 
    Rinkevich Y, Mori T, Sahoo D et al. 2012. Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat. Cell Biol. 14:1251–60
     [Google Scholar]
  85. 85. 
    Wynn TA, Vannella KM. 2016. Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44:450–62
     [Google Scholar]
  86. 86. 
    Hinz B, Lagares D. 2020. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat. Rev. Rheumatol. 16:11–31
     [Google Scholar]
  87. 87. 
    Wernig G, Chen SY, Cui L et al. 2017. Unifying mechanism for different fibrotic diseases. PNAS 114:4757–62
     [Google Scholar]
  88. 88. 
    Cui L, Chen SY, Lerbs T et al. 2020. Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nat Commun 11:2795
     [Google Scholar]
  89. 89. 
    Lerbs T, Cui L, King ME et al. 2020. CD47 prevents the elimination of diseased fibroblasts in scleroderma. JCI Insight 5:e140458
     [Google Scholar]
  90. 90. 
    Tsai JM, Sinha R, Seita J et al. 2018. Surgical adhesions in mice are derived from mesothelial cells and can be targeted by antibodies against mesothelial markers. Sci. Transl. Med. 10:eaan6735
     [Google Scholar]
  91. 91. 
    Koyama Y, Wang P, Liang S et al. 2017. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. J. Clin. Investig. 127:1254–70
     [Google Scholar]
/content/journals/10.1146/annurev-med-042420-104436
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error